96 related articles for article (PubMed ID: 27402142)
21. Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6-minute walk test.
Jayaram L; Wong C; McAuley S; Rea H; Zeng I; O'Dochartaigh C
COPD; 2013 Aug; 10(4):466-72. PubMed ID: 23875741
[TBL] [Abstract][Full Text] [Related]
22. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
23. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
24. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.
Cazzola M; Di Marco F; Santus P; Boveri B; Verga M; Matera MG; Centanni S
Pulm Pharmacol Ther; 2004; 17(1):35-9. PubMed ID: 14643169
[TBL] [Abstract][Full Text] [Related]
25. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
26. Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis.
Tang B; Wang J; Luo LL; Li QG; Huang D
Int J Chron Obstruct Pulmon Dis; 2019; 14():757-766. PubMed ID: 31015757
[TBL] [Abstract][Full Text] [Related]
27. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
28. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
29. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
30. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
[TBL] [Abstract][Full Text] [Related]
32. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis.
Rodrigo GJ; Nannini LJ
Pulm Pharmacol Ther; 2007; 20(5):495-502. PubMed ID: 16621638
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease.
Feng JF; Ding GR; Xie YZ; Zhao D; Wang X
Medicine (Baltimore); 2018 Jun; 97(22):e10841. PubMed ID: 29851792
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
35. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
36. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Cazzola M; Noschese P; Salzillo A; De Giglio C; D'Amato G; Matera MG
Respir Med; 2005 May; 99(5):524-8. PubMed ID: 15823447
[TBL] [Abstract][Full Text] [Related]
37. The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.
Eriksson G; Calverley PM; Jenkins CR; Anzueto AR; Make BJ; Lindberg M; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():1457-1468. PubMed ID: 28553098
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
Zou Y; Xiao J; Yang DH; Li J; Chen Q
COPD; 2016 Aug; 13(4):499-508. PubMed ID: 26846588
[TBL] [Abstract][Full Text] [Related]
39. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
40. Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease.
Yasui H; Inui N; Furuhashi K; Nakamura Y; Uto T; Sato J; Yasuda K; Takehara Y; Suda T; Chida K
Pulm Pharmacol Ther; 2013 Jun; 26(3):336-41. PubMed ID: 23340058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
